Biotherapeutic Technology Company Announces Commercial Offering For AI-Driven Drug Discovery

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution, featuring a customizable Application Programming Interface (API), enables the integration of sizable databases and electronic health records with large language models, thereby enhancing AI-driven drug discovery capabilities. $IPA.US$